drugset / Trial / NCT02108288

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

NCT02108288

Phase 1 Completed 30 enrolled Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-label

Summary

OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.

Timeline

Start
2014-04
Primary completion
2014-05
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carteolol Small molecule
Comparator Latanoprost Small molecule
Subject OPC-1085EL Unknown